Introduction
The impact of elevated serum cholesterol for the development of cardiovascular disease can be reduced by a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor therapy, at least in middle-aged males (1-5). However, the benefit of these drugs in preventing after the cessation of any pharmacological treatment for hyperlipidemia for at least 3 months prior to enrolment in this study. Pravastatin administration started within 2 months after randomization.
Patients were followed for 3-5 years. During this period, reports of endpoints and pravastatin continuation or discontinuation were obtained every 3 months by mail. Fasting serum lipid levels (TC, TG, and HDL-C), blood pressure, and body weight were measured before and one, 3, and 6 months after the initiation of pravastatin treatment and every 6 months thereafter.
Low-density lipoprotein cholesterol (LDL-C) levels were calculated using Friedwald's formula (11), unless TG levels were400 mg/ dL. When LDL-C levels could not be calculated, LDL-C levels were treated as being absent for the purposes of analysis.
Hypertension was defined as systolic blood pressure of 160 mmHg and/or diastolic blood pressure of 90 mmHg and/or the use of antihypertensive drugs.
Endpoints
The primary endpoint of the trial was the combined incidence of any type of fatal and nonfatal CVEs including CVD, cardiac disease, peripheral vascular disorder (PVD), and sudden death. CVD included cerebral infarction, cerebral hemorrhage, transient ischemic attack (TIA), and subarachnoidal hemorrhage.
Cardiac diseases included MI, AP, congestive heart failure due to ischemic heart disease, and arrhythmia requiring pharmacological treatment ; PVD included ASO, dissecting aortic aneurysm, and peripheral arterial thrombosis.
The secondary endpoints were the combined incidence of MI and AP, and death from all causes.
The definition of cardiovascular events were essentially the same as the Lipid Research Clinics Program (12). For the diagnosis of CVD, computed tomography or magnetic resonance imaging findings were also used in this study. Details of definitions of endpoints are described in Appendix 2.
Potential endpoints were reviewed and classified by the Case/Event Evaluation Committee, which was blinded to the identity and group allocation of patients.
When the primary report of an event was inadequate, the additional information required for a judgement to be made was requested.
Lipid standardization
Serum lipid levels were determined using enzymatic cholesterol and TG assays.
The accuracy and precision of TC, TG, and HDL-C determinations at each institution were assessed by a standardization of lipid determination according to the Lipid Standardization Program of the Centers for Disease Control and Prevention, Atlanta, GA, USA. Accuracy, expressed as the mean %bias for TC, TG, and HDL-C was -1.78+2.24 (mean +SD), 0.57+ 6.75, and 2.04+6.64%, respectively. Precision, expressed as mean coefficient of variation for TC, TG, and HDL-C was 0.85+0.66, 1.39+2.21, and 1.85+1.42, respectively. A detailed analysis of the standardization of lipid determination was reported previously (13).
Assessment of compliance and safety
During the follow-up period, pravastatin continuation and discontinuation were reported every 3 months by mail. Routine medical examinations, including physical examination, peripheral blood cell counts, and blood chemistry (liver and renal function tests, and creatine kinase (OK]), were performed by physicians in charge at least every 6 months.
Adverse events were defined as any new unfavorable symptom or worsening of symptoms existing at the baseline, or any unfavorable change in laboratory findings. The study investigator classified each adverse event into one of 4 categories according to its relationship to pravastatin treatment : definite ; possible ; definitely not ; and unknown. With the exception of the third category, all categories were considered to be an adverse drug reaction (ADR) related to pravastatin therapy. The Case/ Event Evaluation Committee also recorded the severity of each ADR as grades 1, 2, or 3 based on World Health Organization criteria (14).
Sample size
Ito and Araki (15) demonstrated that the hazard of ischemic heart disease in Japanese elderly with diabetes mellitus was 0.0307/year. Since the incidence of ischemic heart disease is considered to be higher in patients with hypercholesterolemia than in patients with diabetes mellitus, we postulated the hazard to patients with hypercholesterolemia was 1.5-fold higher than that of patients with diabetes mellitus, i.e. 0.046/year.
It was also suggested that the hazard ratio of group L compared with group S was 1.6 to 1.8. Under these conditions, 400 subjects in each group needed to be included and followed up for four years to have a power of 80% based on the log-rank test with a one-sided significance level of 0.05 (16).
Statistical analysis
Analyses were performed on an intention-to-treat basis unless otherwise indicated. The least-square means calculated using general linear models were used to assess changes in serum lipids before and after pravastatin treatment. Statistical differences between the 2 groups in changes in serum lipids before and after pravastatin were assessed by the analysis of variance [ANOVA] for repeated measurements.
Statistical differences in the incidence of the primary and the secondary endpoints between the 2 groups were assessed using the log-rank test, generalized Wilcoxon test, and Cox regression analysis. Two-sided probability values of 0.05 were considered to indicate a statistically significant difference in endpoint analyses. When appropriate, the Wilcoxon or chi-square test was used to analyse the difference between the study groups.
Values are expressed as the mean +SD unless otherwise indicated.
All statistical analyses were performed using SAS Release 6.12.
Study organization
Study organization of this study, role and member of each committee were described in Appendix 3 (Fig. 6) 
Results
Between January 1, 1991 and March 31, 1993, 703 patients were enrolled in the study and randomly assigned to the 2 study groups. After randomization, 38 patients were excluded from the trial for the following reasons : no attendance at hospital after registration, 19 patients ; withdrawal of informed consent, 6 patients ; other hypocholesterolemia regimen in use at the start of pravastatin treatment, 4 patients ; duplicate entry, 3 patients ; active malignancy, 3 patients ; familial hypercholesterolemia, 2 patients ; and secondary hypercholesterolemia due to hypothyroidism, 1 patient. The remaining 665 patients were followed up.
Baseline characteristics
There were no significant differences in the baseline characteristics of the eligible patients between the 2 groups, except the male : female ratio (Table 1) . The proportion of women in group L (254/334 ; 76%) was significantly lower than that in group S (273/331 ; 82%) .
Compliance with pravastatin treatment
The cumulative percentage of patients who discontinued pravastatin treatment during the trial was 23.9%, and the discontinuation rates in 2 groups (26 .5% in group S and 21.3% in group L) were similar. The mean pravastatin doses for groups L and S through the study were 4.5+0.1 mg/day and 8.3+0.1 mg/day, respectively . Fig. 1 shows changes in TC and LDL-C levels from the baseline during the follow-up period. TC levels decreased 28-32 mg/dL (11-13% reduction) from baseline between 3 months and 3 years after the initiation of treatment in group L and by 38-42 mg/dL (15-17% reduction) in group S (Figs. 1A, 1B). The LDL-C levels decreased 30-34 mg/dL (17-20% reduction) from baseline in group L and by 39-43 mg/dL (23-26% reduction) in group S (Figs . 1C,  1D ). The reductions in TC and LDL-C were significantly greater in group S than in group L through all time points (average group effect, P < 0.0001 by ANOVA). Moreover, although the serum TG levels decreased in both groups , the decrease in group S was significantly greater than that in group L at all time points except at 6 months after the initiation of pravastatin (average group effect, P=0.001 by ANOVA) (Fig. 2A) . In addition, significantly greater increases in HDL-C were observed in group S than in group L (average group effect, P=0.003 by ANOVA) (Fig.  2B ).
Reductions in lipid levels

Endpoint
Patients in this trial were followed for 3-5 years (mean follow-up period : 3.9 years in both groups) . During the follow-up period, 42 and 29 fatal and nonfatal CVEs were observed in groups L and S, respectively ( Table 2) . The proportion of patients who did not experience a primary endpoint (fatal and nonfatal CVEs) was higher in group S than in group L (P=0.046, generalized Wilcoxon test ; P= , group S ; , group L. Each data point shows the least-squares mean +SE.
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0.096, log-rank test) (Fig. 3) . The risk ratio for group S compared with group L, calculated from log-rank scores , was 0.674 (95% confidence interval [CI] , 0.423-1.074) (Fig. 4) . In addition, a similar risk ratio for group S compared with group L (0.697 [95%CI : 0 .433-1.124]) was obtained by Cox regression analysis adjusted for gender, age, diabetes mellitus, previous history of vascular disease (MI, AP, CVD and ASO), cigarette smoking and hypertension.
The differences in the incidence of primary endpoint between groups L and S were further compared in subgroups. When subjects were divided into subgroups according to baseline age, TC, TG or HDL-C, each median value was used as a cut-off point. The existence of an interaction between the subgroups and the treatment groups was also examined using the Cox regression model. No interaction P value between the subgroups was significant. However, taking the low power of the interaction test into account, the low P values and the confidence intervals of the risk ratios suggest that the risk reduction for CVE occurrence in group S was more clear in patients without diabetes mellitus, those with serum cholesterol of <253 mg/dL, and those with TG of 133 mg/dL (Table 3) .
The secondary endpoints were the combined incidence of MI and AP, and death from any cause. The combined total numbers of patients experiencing MI and AP were 17 in group L and 10 in group S. During the follow-up period, 20 and 14 deaths were observed in groups L and S, respectively. Six of the 20 deaths in group L and 8 of the 14 deaths in group S were due to cardiovascular diseases. Of the remaining 14 and 6 deaths in groups L and S, , group S ; , group L. Each data point shows the least-squares mean +SE. respectively, 6 in group L and 2 in group S were due to malignant neoplasia. The secondary endpoint risk ratios for group S compared with group L are shown in Fig. 4 . The statistical power of the study to detect differences in this endpoint was not assured because of the small number of patients.
However, the tendencies were similar to those observed in the primary endpoint analysis .
Risk ratios for group S compared with group L were clearly lower in patients with diabetes mellitus or previous cardiovascular disease in comparison with each counterpart (Table 3) . Therefore, we further compared the incidence of the primary endpoint in groups S and L excluding patients with diabetes mellitus and previous cardiovascular disease.
The difference in the proportion of CVEfree patients between groups S and L increased in statistical significance (P=0.026, generalized Wilcoxon test ; P=0.032, log-rank test) (Fig. 5) .
Safety of pravastatin treatment
The prevalence of adverse events other than CVEs and malignant disease was similarly low in groups L (19 events in 18 cases) and S (26 events in 20 cases) . The ADRs mainly observed in this study were slight elevations of CK and gastrointestinal symptoms . Furthermore, all adverse events, except 2 grade 2 events in group S (in 1 patient blood urea nitrogen levels increased from 20 mg/dL to 27 mg/dL and in the other from 21 mg/dL to 29 mg/dL) and 1 grade 2 event in group L (peripheral leukocyte counts decreased from 3,900 cells/p1 to 2 ,400 cells/,u1), were of grade 1. All grade 2 adverse events were normalized during continuation of drug therapy and no serious adverse events were reported in this trial .
Discussion
This study was the first randomized controlled trial in hypercholesterolemic elderly patients comparing the effects of low and standard doses of pravastatin with the Fig. 3 . Kaplan-Meier curves for the probability of remaining free of the primary endpoint during the follow-up period . Group S, n=331 ; group L, n=334.
The proportion of patients who did not experience a primary endpoint (fatal and nonfatal CVEs) was significantly higher in group S than in group L (p= 0.046, generalized Wilcoxon test ; p =0 .096, log-rank test). Risk ratios and 95% Cls for the primary and secondary endpoints in group S compared with group L . Risk ratios were calculated from log-rank scores.
Fig. 5. Kaplan-Meier curves for the probability of remaining free of the primary endpoint in patients without both diabetes mellitus and previous cardiovascular disease (n= 334). Group S, n=171, 4 events ; group L , n =163, 12 events.
The proportion of patients who did not experience a primary endpoint was significantly higher in group S than in group L (p =0.026, generalized Wilcoxon test ; p =0 .032, log-rank test). Events in the Elderly 39
incidence of CVEs. This study was designed in 1990, and started from January, 1991. At that time, results of prospective interventional studies such as the West of Scotland Coronary Prevention Study (WOSCOPS) (3) and the Scandinavian Simvastatin Survival Study (4S) (4) had not been reported. At that time, the relationships between cholesterol lowering and cardiovascular events in the elderly had not been clarified. Furthermore, it was indicated that there was a possible association between low cholesterol levels and the risk of hemorrhagic stroke. For these reasons, all CVEs including cerebral hemorrhage were employed as primary endpoints. The combined incidences of MI and AP were employed as secondary endpoints.
In this study, it was demonstrated that the standard dose of pravastatin for Japanese, 10-20 mg/day, was more effective in reducing the incidence of CVEs in elderly hypercholesterolemic patients than the low dose, 5 mg/day (Figs. 3, 4) . Risk reduction for the primary endpoint (the combined incidence of fatal and nonfatal CVEs) for group S compared with group L, was calculated from log-rank scores as 33%. Furthermore, risk reductions in group S were 42% and 29% for the secondary endpoints, the combined incidence of MI and AP, and death from all causes, respectively.
In the subanalysis of the Cholesterol and Recurrent Events (CARE) trial (5, 17), pravastatin treatment was demonstrated to be effective in the secondary prevention of coronary heart disease in elderly patients with normal or slightly elevated cholesterol levels. In addition, subanalysis of WOSCOPS (4) has demonstrated that pravastatin treatment is effective in the primary prevention of coronary heart disease in hypercholesterolemic patients aged 55 years as well as in patients aged <55 years. Risk reductions by pravastatin treatment for CVE observed in elderly subgroups in the CARE and WOS-COPS studies were similar to that observed in the present study. However, the doses of pravastatin used in this trial were 5 mg/day and 10-20 mg/day and the difference between these doses is smaller than that in the CARE and WOSCOPS studies in which the difference in dose was 40 mg/day.
As a result, the difference in the TC levels between the groups, 10-14 mg/dl, was smaller than that reported in those previous studies.
It is unclear how small differences in TC and LDL-C on pravastatin treatment between the 2 groups in the present study resulted in a substantial risk reduction for CVEs. These findings and those of the present study may indicate the importance of some ancillary effects of pravastatin other than its cholesterol-lowering effect in reducing the incidence of CVEs. Anti-platelet thrombus formation activity (20) and an endothelial function protective effect (21) of pravastatin may have a role, since platelet functions increase and endothelium functions deteriorate in the elderly (22, 23).
One other possible explanation for marked difference in the incidence of CVEs between the 2 groups in the present study despite the small difference in on-treatment TC levels is that a threshold TC level for the effect of cholesterol-lowering to reduce the occurrence of CVEs may exist. The subanalysis suggested a clear difference between groups L and S among those with TC levels of < 253 mg/dL, but not in those with TC levels of 253 mg/ dL (Table 3 ). The insufficient decreases in the TC and LDL-C levels in those with the initial TC levels of >_253 mg/dL on the test dose in this study may explain these findings. The on-treatment TC levels after pravastatin were about 205 mg/dL and 215 mg/dL, respectively, in groups S and L in those who had TC levels of <253 mg/ dL, and 215 mg/dL and 225 mg/dL, in groups S and L in those who had TC levels of 253 mg/dL, respectively. These findings suggest that the threshold TC level for the effect of cholesterol-lowering to reduce the occurrence of CVEs in elderly Japanese may lie between 205 mg/dL and 215 mg/dL in the on-treatment TC level.
The proportion of males in group L was significantly higher than that in group S (Table 1 ). The LIPID study (24) and the subanalysis of the CARE study (25) demonstarated that the effect of pravastatin in reducing the incidence of coronary heart disease and stroke , respectively, was more prominent in males than in females. Therefore , the difference in gender distribution in the 2 arms of the present study may have influenced the results. However, Cox regression analysis adjusted for gender, age, diabetes mellitus, PVD, cigarette smoking, and hypertension produced similar risk ratios between groups S and L . Thus, the difference in gender distribution between groups S and L appeared to have no crucial effect on the results.
The risk ratios suggest that the difference between groups L and S in the CVE incidence was more marked in subjects without diabetes mellitus and in those with TG levels of 133 mg/dL, as well as in subjects with TC levels of <253 mg/dL (Table 3) . We also showed that the significance of the difference in the incidence of CVEs between the 2 groups became greater when patients with both diabetes mellitus and previous cardiovascular disease were excluded (Fig. 5) .
Although the reason(s) for these findings remain unclear, the number of patients in the present study was insufficient for further analyses to clarify the reasons for the findings of subgroup analyses.
Compliance with the oral administration of pravastatin in this trial was fairly good, with the cumulative rate of pravastatin discontinuation being 23.9%. This figure is similar to or better than that observed in previous studies : the discontinuation rate was 24.7% at year 4 in WOS-COPS (4) and 31.3% at year 4 in the Helsinki Heart Study (2). In addition, the tolerability of pravastatin was good, and no significant adverse effects were observed in the present study.
From the findings obtained, together with recent studies demonstrating hypercholesterolemia is one of the important risk factors even in the elderly (26-32), it is suggested that hypercholesterolemia in the elderly is a morbid state requiring treatment and that pravastatin at the standard dose (10-20 mg/day) is more useful in the treatment of elderly hypercholesterolemic patients to reduce the incidence of cardiovascular disease than low-dose pravastatin. While the Japanese standard dose of 10-20 mg/ dl is lower than that generally used in western countries, the fat intake and the body size of Japanese, especially the elderly, is also smaller. These differences in the fat intake and the body size and the characteristics of patients in this study who had only mild hypercholesterolemia (serum TC of 220-280 mg/dL), may explain why pravastatin 10-20 mg/day was effective in reducing the incidence of CVEs in this study population.
Further studies are needed to elucidate whether a higher dose of pravastatin could reduce the CVE incidence in elderly Japanese patients with higher serum TC levels or in younger patients. (1) Its site must include the sternum (any level) (2) It must occur during a form of exertion or stress and must usually last at least 30 sec (3) It must on most occasions disappear within 10 min or less from the time with rests or decreases the intensity of the exertion (4) It must usually be relieved in 2-5 min by nitroglycerine(does not apply if nitroglycerine has never been taken)
In the case with angina pectoris at the baseline, chest pain or discomfort should disappeared or be controlled at entry. Reappearance or exacerbation of chest pain or discomfort with characteristics fulfilled by (1)-(4) was considered as an event. Subjects with uncontrolled angina pectoris at entry were not enrolled into this study. In cases with ASO at the baseline,symptoms should be controlled not to disturb daily life and the gangrene or ulcer should be healed. Reappearance or exacerbation of symptoms was considered as an event.
V. Cerebrovascular disease
A diagnosis requires all of the following :
(1) History of recent onset of unequivocal and objective findings of a localizing neurologic deficit documented by a physician (2) Findings persist longer than 24 hr (3) The neurologic findings are not referable to an extracranial lesion (4) Findings of a computed tomographic (CT) or magnetic resonance image (MRI) taken within 3 weeks after onset, or autopsy record to classify the cerebrovascular disease into cerebral hemorrhage, cerebral infarction or subarachnoidal hemorrhage. Cerebral infarction was defined as a stroke accompanied by CT and/or MRI scan(s) that showed an infarct in the expected area on the basis of the clinical findings or a stroke for which there was evidence of cerebral infarction at autopsy. Cerebral hemorrhage and subarachnoidal hemorrhage were classified on the basis of evidence obtained on CT or MRI scan or at autopsy,excluding hemorrhagic conversion of infarction.
In cases with cerebrovascular disease at the baseline, the appearance of new unequivocal and objective findings of a localizing neurologic deficit documented by a physician which persist longer than 24 hr was considered as an event and classified on the basis of evidence obtained on CT or MRI scanning or at autopsy.
Cerebral infarction without obvious neurologic symptoms demonstrated by CT or MRI scan taken incidentally was not considered as an event.
VI. Transient cerebral ischemic attack
(1) History of sudden onset of symptoms of a localizing neurologic deficit 
